Department of Nephrocardiology, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, ul. Zeromskiego 113, 90-549 Lodz, Poland.
Int J Mol Sci. 2023 Aug 27;24(17):13288. doi: 10.3390/ijms241713288.
Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks for the development and progression of cardiovascular diseases. These conditions are characterized by elevated levels of total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein cholesterol (LDL-C). This review delves into the current treatment approach, focusing on equalizing these parameters while enhancing the overall quality of life for patients. Through an extensive analysis of clinical trials, we identify disorders that necessitate alternative treatment strategies, notably familial hypercholesterolemia. The primary objective of this review is to consolidate existing information concerning drugs with the potential to revolutionize dyslipidemia management significantly. Among these promising pharmaceuticals, we highlight alirocumab, bempedoic acid, antisense oligonucleotides, angiopoietin-like protein inhibitors, apolipoprotein C-III (APOC3) inhibitors, lomitapide, and cholesterol ester transfer protein (CETP) inhibitors. Our review demonstrates the pivotal roles played by each of these drugs in targeting specific parameters of lipid metabolism. We outline the future landscape of dyslipidemia treatment, envisaging a more tailored and effective therapeutic approach to address this widespread medical concern.
血脂异常已成为患者中常见的疾病，对心血管疾病的发生和发展构成重大风险。这些疾病的特征是总胆固醇（TC）、甘油三酯（TGs）和低密度脂蛋白胆固醇（LDL-C）水平升高。本综述深入探讨了当前的治疗方法，重点是在提高患者整体生活质量的同时，使这些参数达到平衡。通过对临床试验的广泛分析，我们确定了需要替代治疗策略的疾病，特别是家族性高胆固醇血症。本综述的主要目的是整合具有显著改变血脂异常管理潜力的药物的现有信息。在这些有前途的药物中，我们重点介绍了阿利西尤单抗、贝匹达酸、反义寡核苷酸、血管生成素样蛋白抑制剂、载脂蛋白 C-III（APOC3）抑制剂、洛美他派和胆固醇酯转移蛋白（CETP）抑制剂。我们的综述表明，这些药物中的每一种在针对脂质代谢的特定参数方面都发挥了关键作用。我们概述了血脂异常治疗的未来前景，设想采用更具针对性和更有效的治疗方法来解决这一广泛存在的医学问题。
